ABP-688 C-11 (8 (3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enoneO-11C-methyl-oxime), a noncompetitive and highly selective antagonist for the metabotropic glutamate receptor subtype 5 (mGluR5). It is a promising PET ligand for the quantification of mGlu5 receptors in humans and animals. It readily crosses the blood-brain barrier. The temporal and spatial changes in mGluR5 availability suggest ABP-688 C-11 PET imaging in epilepsy provide abnormal glutamatergic network during epileptogenesis. ABP-688 C-11 was used in receptors imaging in Major Depressive disorder, chronic neuropathic pain, anxiety and other brain disease investigations.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16595505 | https://www.ncbi.nlm.nih.gov/pubmed/17110115
Curator's Comment: # Novartis
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3227 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25156701 |
1.7 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
|||
Diagnostic | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. | 2006 Apr |
|
In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5. | 2015 Feb 1 |
|
In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [(11)C]ABP688 and [(18)F]FPEB. | 2017 Aug |
|
Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [(11)C]ABP688 and PET imaging study in depression. | 2018 Apr |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17110115
ABP688 was originally shown to be a potent antagonist of quisqualate-induced phosphoinositol (PI) accumulation in L(tk-) cells expressing recombinant human mGluR5 (hmGluR5), with an IC50 value of 2.4 nM (95% CI: 0.5–12 nM) . In the same preparation, ABP688 completely inhibited glutamate-induced calcium release with an IC50 value of 2.3 nM (95% CI: 2.1–2.5) nM and had no effect, up to 10 uM, on ATP-induced PI accumulation via stimulation
of endogenously expressed purinergic receptors in hmGluR5-expressing cells, or on quisqualate-induced PI accumulation in hmGluR1-expressing cells.
Substance Class |
Mixture
Created
by
admin
on
Edited
Sat Dec 16 15:02:47 GMT 2023
by
admin
on
Sat Dec 16 15:02:47 GMT 2023
|
Record UNII |
08AF38N151
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
849469-02-9
Created by
admin on Sat Dec 16 15:02:47 GMT 2023 , Edited by admin on Sat Dec 16 15:02:47 GMT 2023
|
PRIMARY | |||
|
08AF38N151
Created by
admin on Sat Dec 16 15:02:47 GMT 2023 , Edited by admin on Sat Dec 16 15:02:47 GMT 2023
|
PRIMARY |
All of the following components must be present:
UNSPECIFIED SUBSTANCE
(not present in database)
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->RADIOLIGAND |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|